Scynexis
SCYXSCYX · Stock Price
Historical price data
Overview
Scynexis has successfully transitioned to a commercial-stage biotech with the FDA approval of BREXAFEMME® (ibrexafungerp) for vulvovaginal candidiasis, now exclusively licensed to GSK. Its core innovation is the fungerp platform, a first-in-class triterpenoid antifungal with a novel mechanism of action. The company's strategy involves leveraging partnerships for commercialization while advancing a next-generation pipeline, including SCY-247, to tackle life-threatening, drug-resistant invasive fungal infections and, following a recent acquisition, exploring new therapeutic areas like polycystic kidney disease.
Technology Platform
Proprietary fungerp platform: a first-in-class family of oral and intravenous triterpenoid antifungal agents that inhibit glucan synthase, a key enzyme for fungal cell wall synthesis, offering a novel mechanism of action against resistant pathogens.
Pipeline
18| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Ibrexafungerp | Invasive Candidiasis | Phase 3 | |
| SCY-078 | Candidiasis, Invasive | Phase 3 | |
| Ibrexafungerp | Vulvovaginal Candidiasis | Phase 3 | |
| Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet | Recurrent Vulvovaginal Candidiasis | Phase 3 | |
| SCY-078 + Fluconazole + Echinocandin | Candidiasis, Invasive | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
In antifungals, Scynexis competes with established drug classes and novel agents from Cidara and F2G, differentiated by its first-in-class oral/IV fungerp mechanism. In ADPKD, PXL-770 will compete with tolvaptan and other clinical-stage candidates, with its novel AMPK activation as a potential differentiator.